Related Experiment Video

Updated: Sep 25, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Molecular aspects of resistance to antitumor platinum drugs

Viktor Brabec1, Jana Kasparkova

  • 1Institute of Biophysics, Academy of Sciences of the Czech Republic, Kralovopolska 135, Brno, Czech Republic. brabec@ibp.cz

Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|September 19, 2002
PubMed

Insights

Understanding platinum drug resistance in cancer is crucial. Sulfur compounds influence DNA modifications and repair, impacting drug effectiveness and potentially altering resistance pathways for new platinum-based therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Platinum-based drugs are vital in cancer chemotherapy, but tumor cell resistance limits their clinical efficacy.
  • Cellular resistance to platinum drugs is a significant obstacle, necessitating research into underlying molecular mechanisms.
  • Platinum drug activity is linked to DNA adduct formation, making DNA modification and repair central to understanding resistance.

Purpose of the Study:

  • To review recent findings on how sulfur-containing compounds affect DNA modifications by platinum-based anticancer drugs.
  • To explore the mechanisms of DNA adduct repair and their recognition by cellular proteins in the context of platinum drug resistance.
  • To evaluate how altering platinum drug structures impacts DNA binding, resistance pathways, and pharmacological properties.

Main Methods:

  • Literature review of studies investigating platinum-DNA adducts and cellular processing.
  • Analysis of research on the role of sulfur-containing compounds in modulating platinum drug interactions with DNA.
  • Examination of data on DNA repair pathways and damaged-DNA binding proteins in platinum drug resistance.

Main Results:

  • Sulfur-containing compounds influence the nature of DNA modifications induced by platinum complexes.
  • Enhanced repair of platinum-DNA adducts is a key factor in tumor cell resistance.
  • Cellular recognition of modified DNA by binding proteins is linked to repair processes.
  • Altering platinum drug structures to change DNA binding modes can circumvent existing resistance mechanisms.

Conclusions:

  • Modulating DNA modification and repair pathways, potentially via sulfur-containing compounds or altered drug structures, is key to overcoming platinum drug resistance.
  • Developing novel platinum drugs with different DNA binding modes may overcome resistance and improve therapeutic outcomes.
  • Understanding the interplay between DNA adduct formation, repair, and protein recognition is essential for designing more effective platinum-based cancer therapies.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...